En Okodia, la calidad lingüística no es solo un objetivo, sino una metodología de trabajo. Nuestro compromiso se refleja en la obtención de certificaciones como la ISO 17100, ISO 18587 y la ISO 9001, tres estándares clave que garantizan procesos sólidos y resultados fiables. Si buscas un proveedor...
Artificial intelligence has become a common tool in content translation, including in the healthcare sector. However, when it comes to medical documentation, the margin for error becomes a clinical and legal risk. And more and more regulatory bodies are focusing on this. The false sense of...
Health tourism in Europe continues to grow, driven by international mobility and the search for specialised treatments. According to the Organisation for Economic Co-operation and Development, this sector represents billions of euros annually and will continue to grow in the coming years. However, many clinics are...
Pharmaceutical translation plays a decisive role in assessing the benefit-risk balance of a medicine in Europe. It is not just about transferring scientific information between languages, but ensuring that every term maintains its regulatory and clinical meaning. In safety reports and documentation submitted to authorities,...
Clinical trial translation has become a strategic part of European regulatory compliance. Since the full application of Regulation (EU) 536/2014 and centralised management through the Clinical Trials Information System (CTIS), consistency in documentation has become a matter of linguistic quality and regulatory risk. A term...
In many projects, multilingual informed consent is the document that ultimately determines whether your timeline stays on track or falls apart. Few things are more frustrating for a CRO than having everything ready for site activation, only to become stuck because the consent forms in...
More and more clinical trials depend on what patients report: symptoms, quality of life, and the impact of treatment on their daily lives. These are PROs in clinical trials, and in 2026 they sit at the centre of the regulatory conversation. The problem is that a...
CROs live surrounded by documents: protocols, amendments, investigator manuals, consent forms, recruitment materials, safety reports, scientific publications and more. When each country, each team or each provider manages translations "in their own way", the result is predictable: inconsistencies, rework, data at risk and uncontrolled costs. Centralised...
In a multinational clinical trial, it is enough for a single sentence to be poorly translated for the whole study to falter: misinformed patients, invalid data, regulatory delays running into millions of dollars. Medical and pharmaceutical translation is no longer an "extra," but a central...
Imagine you’ve got everything ready to launch an international clinical trial… and a single ambiguous sentence in the translated protocol delays approval by three months. It happens more often than you’d think. In biomedical research, one word can mean the difference between an approved study...